摘要
目的 探讨超重2型糖尿病(T2DM)患者采用司美格鲁肽联合二甲双胍治疗的临床效果。方法 选择2021年7月—2023年8月本院收治的共计132例超重T2DM患者作为研究对象,以随机数表法分为研究组和对照组两组,每组各66例。对照组给予二甲双胍治疗,研究组给予司美格鲁肽联合二甲双胍治疗,比较两组血糖水平、血压水平、胰岛素抵抗指数、体成分、血脂水平、血糖波动指标及不良反应发生情况。结果 治疗后两组空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbAlc)水平下降(P<0.05),研究组较对照组更低(P<0.05);治疗后两组收缩压(SBP)、舒张压(DBP)水平下降(P<0.05),研究组较对照组更低(P<0.05);治疗后两组稳态模型胰岛素抵抗指数(HOMA-IR)下降(P<0.05),研究组较对照组更低(P<0.05);治疗后两组体质量指数(BMI)、全身总脂肪组织质量下降(P<0.05),研究组较对照组更低(P<0.05);两组治疗前后全身总瘦组织质量比较,差异无统计学意义(P>0.05);治疗后两组总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)水平下降(P<0.05),高密度脂蛋白胆固醇(HDL-C)水平升高(P<0.05),研究组TC、TG、LDL-C水平较对照组更低(P<0.05),HDL-C水平更高(P<0.05);治疗后两组平均血糖标准差(SDBG)、平均血糖波动幅度(MAGE)、日间血糖平均绝对差(MODD)、最大血糖波动幅度(LAGE)下降(P<0.05),达标范围内时间(TIR)3.9~10.0升高(P<0.05),研究组SDBG、MAGE、MODD、LAGE较对照组更低(P<0.05),TIR3.9~10.0更高(P<0.05);统计不良反应发生率,研究组为4.55%(3/66),与对照组的10.61%(7/66)比较无显著差异(P>0.05)。结论 司美格鲁肽联合二甲双胍应用于超重T2DM患者治疗中,能够降低血糖、血压水平,减轻胰岛素抵抗,降低BMI及全身总脂肪组织质量,改善血脂水平,控制血糖波动,安全性较高。
Objective To explore the clinical effect of semaglutide combined with metformin on overweight type 2 diabetes(T2DM)patients.Methods A total of 132 overweight T2DM patients who were admitted in our hospital from July 2021 to August 2023 were selected as the study subjects.They were randomly divided into the study group and the control group according to random number table method,with 66 cases in each group.The control group was treated with metformin,while the study group was treated with semaglutide and metformin.Blood glucose levels,blood pressure levels,insulin resistance index,body composition,blood lipid levels,blood glucose fluctuation indicators,and incidence of adverse reactions were compared between the two groups.Results After treatment,the fasting blood glucose(FPG),2-hour postprandial blood glucose(2-hour PG),and glycated hemoglobin(HbAlc)levels in both groups were decreased(P<0.05),and in comparison with the control group,the study group was lower(P<0.05).After treatment,the systolic blood pressure(SBP)and diastolic blood pressure(DBP)levels in both groups were decreased(P<0.05),and in comparison with the control group,the study group was lower(P<0.05).After treatment,the HOMA-IR steady-state models in both groups were decreased(P<0.05),and in comparison with the control group,the study group was lower(P<0.05).After treatment,the body mass index(BMI)and total adipose tissue mass in both groups were decreased(P<0.05),and in comparison with the control group,the study group was lower(P<0.05).There was no statistically significant difference in total lean tissue mass in both groups before and after treatment(P>0.05).After treatment,the total cholesterol(TC),triglycerides(TG),and low-density lipoprotein cholesterol(LDL-C)levels in both groups were decreased(P<0.05),while the high-density lipoprotein cholesterol(HDL-C)levels were increased(P<0.05),in comparison with the control group,TC,TG,and LDL-C levels in the study group were lower(P<0.05),and HDL-C level was higher(P<0.05).After treatment,the standar
作者
李婷
孙衍
李娜
Li Ting;Sun Yan;Li Na(Endocrinology Department,Heji Hospital Affiliated to Changzhi Medical College,Changzhi,Shanxi 046000,China)
出处
《齐齐哈尔医学院学报》
2024年第10期923-927,共5页
Journal of Qiqihar Medical University
基金
山西省卫生健康委科研课题计划项目(2022037)。
